Tech Company Financing Transactions
Adaptive Biotechnologies Funding Round
Viking Global Investors participated in a $105 million Series D funding round for Adaptive Biotechnologies. The funding round was announced on 4/8/2014.
Transaction Overview
Company Name
Announced On
4/8/2014
Transaction Type
Venture Equity
Amount
$105,000,000
Round
Series D
Investors
Proceeds Purpose
This investment will enable the Company to expand globally its preeminent immunosequencing research platform and downstream validated clinical diagnostic products.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1551 Eastlake Ave. East 200
Seattle, WA 98102
USA
Seattle, WA 98102
USA
Phone
Website
Email Address
Overview
Adaptive (Nasdaq: ADPT) is at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Chad Robins
Chief Financial Officer
Chad Cohen
Chief Technical Officer
Sean Nolan
Co-Founder
Harlan Robins
Founder
Christopher Carlson
VP - Bus. Development
Julie Rubinstein
VP - General Counsel
Gene DeFelice
VP - Operations
Nancy Hill
VP - Regulatory Affairs
Melina Cimler
Browse more venture capital transactions:
Prev: 4/8/2014: CyVek venture capital transaction
Next: 4/8/2014: Altia Systems venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs